[go: up one dir, main page]

AR090161A1 - Derivados heterociclicos nitrogenados con accion sobre el cancer de vejiga - Google Patents

Derivados heterociclicos nitrogenados con accion sobre el cancer de vejiga

Info

Publication number
AR090161A1
AR090161A1 ARP130100588A ARP130100588A AR090161A1 AR 090161 A1 AR090161 A1 AR 090161A1 AR P130100588 A ARP130100588 A AR P130100588A AR P130100588 A ARP130100588 A AR P130100588A AR 090161 A1 AR090161 A1 AR 090161A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
lower alkyl
aromatic heterocyclic
heterocyclic group
aromatic
Prior art date
Application number
ARP130100588A
Other languages
English (en)
Inventor
Iikubo Kazuhiko
Hisamichi Hiroyuki
Kawamoto Yuichiro
Moritomo Hiroyuki
Suzuki Tomoyuki
Futami Takashi
Suzuki Atsushi
Tsunoyama Kazuhisa
Asaumi Makoto
Tomiyama Hiroshi
Noda Atsushi
Iwai Yoshinori
Tokuzaki Kazuo
Okada Haruki
Miyasaka Kozo
Kameda Minoru
Kuriwaki Ikumi
Original Assignee
Astellas Pharma Inc
Kotobuki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Kotobuki Pharmaceutical Co Ltd filed Critical Astellas Pharma Inc
Publication of AR090161A1 publication Critical patent/AR090161A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se proporciona un compuesto como un agente preventivo y/o terapéutico para el cáncer de vejiga. Como resultado de estudios en compuestos que tienen una acción inhibidora de FGFR, los compuestos heterocíclicos aromáticos que contienen nitrógeno de la presente tienen una acción inhibidora sobre FGFR1, FGFR2 y/o FGFR3, en particular, FGFR3 mutante. El compuesto heterocíclico aromático que contiene nitrógeno se puede usar en forma de un agente terapéutico para diversos cánceres relacionados con FGFR1, FGFR2 y/o FGFR3, tales como cáncer de pulmón y cáncer de mama resistente a terapia hormonal, cáncer de estómago, cáncer de mama triple negativo, cáncer de endometrio, cáncer de vejiga y glioblastoma, en particular como un agente preventivo y/o terapéutico para cáncer de vejiga FGFR3-positivo mutante. Reivindicación 1: Un compuesto de la fórmula (1) o a su sal, (caracterizado porque X e Y, iguales o diferentes entre sí, son CH o N, siempre que X e Y no sean simultáneamente N; L¹ es -alquileno inferior-, -alquileno inferior-O-, -O-alquileno inferior- o -alquinileno inferior-; Z es N o CH; R¹, iguales o diferentes entre sí, son alquilo inferior opcionalmente sustituido con halógeno, -O-(alquilo inferior opcionalmente sustituido con halógeno), halógeno, ciano o -N(alquilo inferior)₂; p es un número entero de 2 a 4; anillo W es un anillo carbocíclico aromático opcionalmente sustituido, un anillo heterocíclico aromático opcionalmente sustituido o un anillo heterocíclico no aromático opcionalmente sustituido; Q es -L²-R² o R³; L² es un anillo heterocíclico aromático opcionalmente sustituido o un anillo heterocíclico no aromático opcionalmente sustituido; R² es un grupo heterocíclico no aromático opcionalmente sustituido con alquilo inferior, cicloalquilo opcionalmente sustituido, alquilo inferior opcionalmente sustituido con uno o varios grupos seleccionados del grupo que consiste en -OH y -O-alquilo inferior, -C(O)-R⁰, -C(O)-cicloalquilo opcionalmente sustituido, -NH-R⁰, -N(alquilo inferior)-R⁰, un grupo -L³-heterocíclico no aromático opcionalmente sustituido o H; R⁰ es alquilo inferior opcionalmente sustituido con -OH; R³ es (i) alquilo inferior opcionalmente sustituido con uno o varios grupos seleccionados del grupo que consiste en -C(O)OH, -OH, -O-R⁰, amino opcionalmente sustituido con uno o dos R⁰, carbamoilo opcionalmente sustituido con uno o dos R⁰, un grupo heterocíclico aromático opcionalmente sustituido, un grupo heterocíclico no aromático opcionalmente sustituido y un grupo -C(O)-heterocíclico no aromático opcionalmente sustituido; (ii) -O-(alquilo inferior opcionalmente sustituido con uno o varios grupos seleccionados del grupo que consiste en -C(O)OH, -OH, -O-R⁰, carbamoilo opcionalmente sustituido con uno o dos R⁰, un grupo heterocíclico no aromático opcionalmente sustituido y un grupo -C(O)-heterocíclico no aromático opcionalmente sustituido); (iii) -NH-(alquilo inferior opcionalmente sustituido con uno o varios grupos seleccionados del grupo que consiste en -OH, un grupo heterocíclico no aromático opcionalmente sustituido con alquilo inferior y carbamoilo opcionalmente sustituido con uno o dos R⁰); (iv) -N(alquilo inferior)-(alquilo inferior opcionalmente sustituido con uno o varios grupos seleccionados del grupo que consiste en -OH, un grupo heterocíclico no aromático opcionalmente sustituido con alquilo inferior y carbamoilo opcionalmente sustituido con uno o dos R⁰); (v) -C(O)OH; (vi) grupo -C(O)-heterocíclico no aromático opcionalmente sustituido; (vii) -O-(un grupo heterocíclico no aromático opcionalmente sustituido con alquilo inferior); o (viii) carbamoilo opcionalmente sustituido con uno o dos R⁰; y L³ es un enlace, -NH-, -N(alquilo inferior)- o alquileno inferior).
ARP130100588A 2012-02-28 2013-02-26 Derivados heterociclicos nitrogenados con accion sobre el cancer de vejiga AR090161A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012042065 2012-02-28

Publications (1)

Publication Number Publication Date
AR090161A1 true AR090161A1 (es) 2014-10-22

Family

ID=49082566

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100588A AR090161A1 (es) 2012-02-28 2013-02-26 Derivados heterociclicos nitrogenados con accion sobre el cancer de vejiga

Country Status (20)

Country Link
US (2) US9464077B2 (es)
EP (1) EP2821402B1 (es)
JP (1) JP5343177B1 (es)
KR (1) KR102032007B1 (es)
CN (1) CN104144915B (es)
AR (1) AR090161A1 (es)
AU (2) AU2013227139B2 (es)
BR (1) BR112014018868B1 (es)
CA (1) CA2866611C (es)
EA (1) EA026953B1 (es)
ES (1) ES2746288T3 (es)
IL (1) IL234313A (es)
MX (1) MX349120B (es)
PH (1) PH12014501925A1 (es)
PL (1) PL2821402T3 (es)
PT (1) PT2821402T (es)
TW (1) TWI542581B (es)
UA (1) UA114501C2 (es)
WO (1) WO2013129369A1 (es)
ZA (1) ZA201406201B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1205528A1 (en) 2012-03-08 2015-12-18 Astellas Pharma Inc. Novel fgfr3 fusion product
US20150203589A1 (en) 2012-07-24 2015-07-23 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
KR102132149B1 (ko) * 2012-07-24 2020-07-09 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 융합 단백질 및 그의 방법
ES2643571T3 (es) 2012-09-27 2017-11-23 Chugai Seiyaku Kabushiki Kaisha Gen de fusión FGFR3 y fármaco que se dirige al mismo
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
US20160052926A1 (en) * 2013-03-15 2016-02-25 Hutchison Medipharma Limited Novel pyrimidine and pyridine compounds and usage thereof
AR097455A1 (es) 2013-08-28 2016-03-16 Astellas Pharma Inc Composición farmacéutica que contiene compuesto de pirimidina como un ingrediente activo
RU2715708C2 (ru) 2013-10-18 2020-03-03 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Ингибиторы fgfr4
EA028614B1 (ru) * 2014-05-22 2017-12-29 Общество С Ограниченной Ответственностью "Русские Фармацевтические Технологии" Селективные ингибиторы, нарушающие взаимодействие рецептора фактора роста фибробластов и frs2, для профилактики и лечения рака
KR102344105B1 (ko) 2014-08-18 2021-12-29 에자이 알앤드디 매니지먼트 가부시키가이샤 모노시클릭 피리딘 유도체의 염 및 이의 결정
KR102839867B1 (ko) * 2014-09-26 2025-07-28 얀센 파마슈티카 엔브이 Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용
JP6503450B2 (ja) 2015-03-25 2019-04-17 国立研究開発法人国立がん研究センター 胆管癌治療剤
SG10201810057UA (en) 2015-04-14 2018-12-28 Eisai R&D Man Co Ltd Crystalline fgfr4 inhibitor compound and uses thereof
CN104940748A (zh) * 2015-06-09 2015-09-30 林正兴 一种治疗胃癌的药物组合物
SG10201913213WA (en) 2015-12-17 2020-03-30 Eisai R&D Man Co Ltd Therapeutic agent for breast cancer
CN106928275B (zh) * 2015-12-29 2020-10-02 齐鲁制药有限公司 螺环胺类芳基磷氧化合物的制备方法及其中间体和晶型
US11357769B2 (en) 2016-05-10 2022-06-14 Eisai R&D Management Co., Ltd. Drug combinations for reducing cell viability and/or cell proliferation
CN108884097B (zh) * 2016-05-20 2021-05-28 浙江海正药业股份有限公司 嘧啶类衍生物、其制备方法和其在医药上的用途
US11236094B2 (en) 2017-08-15 2022-02-01 Cspc Zhongqi Pharmaceuticall Technology (Shijiazhuang) Co., Ltd. Substituted pyrrolo[2,1-f][1,2,4]triazines as FGFR inhibitors
CN111712245A (zh) 2018-03-28 2020-09-25 卫材R&D管理有限公司 用于肝细胞癌的治疗剂
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022148317A1 (zh) * 2021-01-11 2022-07-14 广州市力鑫药业有限公司 2-氨基嘧啶类化合物及其药物组合物和应用
CN112851587A (zh) * 2021-01-21 2021-05-28 药雅科技(上海)有限公司 一种用于治疗癌症的炔类杂环化合物及其制备方法与用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2476281A1 (en) 2002-02-08 2003-08-14 Smithkline Beecham Corporation Pyrimidine compounds
WO2005002673A1 (en) * 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
AU2006227628A1 (en) * 2005-03-16 2006-09-28 Targegen, Inc. Pyrimidine compounds and methods of use
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
WO2007056023A2 (en) * 2005-11-02 2007-05-18 Targegen, Inc. Thiazole inhibitors targeting resistant kinase mutations
WO2007071752A2 (en) 2005-12-21 2007-06-28 Novartis Ag Pyrimidinyl aryl urea derivatives being fgf inhibitors
US8030487B2 (en) 2006-07-07 2011-10-04 Targegen, Inc. 2-amino—5-substituted pyrimidine inhibitors
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
CN101611014B (zh) 2006-12-21 2012-05-30 阿斯利康(瑞典)有限公司 用作fgfr抑制剂的酰氨基吡唑类化合物
BRPI0818658A2 (pt) 2007-10-09 2015-04-14 Merck Patent Ges Mit Beschränkter Haftung Derivados de piridina úteis como ativadores de glicoquinase
WO2009056886A1 (en) * 2007-11-01 2009-05-07 Astrazeneca Ab Pyrimidine derivatives and their use as modulators of fgfr activity
AU2009261683A1 (en) 2008-06-19 2009-12-23 Astrazeneca Ab Pyrazole compounds 436

Also Published As

Publication number Publication date
TWI542581B (zh) 2016-07-21
UA114501C2 (uk) 2017-06-26
IL234313A (en) 2017-03-30
TW201348211A (zh) 2013-12-01
CN104144915B (zh) 2016-08-24
AU2017202759A1 (en) 2017-05-18
AU2013227139A1 (en) 2014-08-28
CN104144915A (zh) 2014-11-12
US20170152232A1 (en) 2017-06-01
KR102032007B1 (ko) 2019-10-14
EP2821402B1 (en) 2019-08-21
BR112014018868A2 (pt) 2017-09-26
ZA201406201B (en) 2015-10-28
US9464077B2 (en) 2016-10-11
KR20140129068A (ko) 2014-11-06
BR112014018868B1 (pt) 2021-02-09
EP2821402A4 (en) 2015-08-19
PT2821402T (pt) 2019-10-02
MX349120B (es) 2017-07-12
EA026953B1 (ru) 2017-06-30
ES2746288T3 (es) 2020-03-05
JP5343177B1 (ja) 2013-11-13
AU2013227139B2 (en) 2017-02-16
EP2821402A1 (en) 2015-01-07
US20140142084A1 (en) 2014-05-22
WO2013129369A1 (ja) 2013-09-06
CA2866611C (en) 2020-01-07
PH12014501925A1 (en) 2014-11-24
EA201491595A1 (ru) 2015-01-30
CA2866611A1 (en) 2013-09-06
JPWO2013129369A1 (ja) 2015-07-30
PL2821402T3 (pl) 2020-01-31
MX2014010327A (es) 2014-10-13
HK1203201A1 (zh) 2015-10-23

Similar Documents

Publication Publication Date Title
AR090161A1 (es) Derivados heterociclicos nitrogenados con accion sobre el cancer de vejiga
AR091858A1 (es) INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
CL2016003301A1 (es) Compuestos derivados del ácido amino-(piridin-4-carboxílico) sustituidos, inhibidores de la histona desmetilasa; composición farmacéutica, que los comprende, útiles en el tratamiento del cáncer, tales como el cáncer de próstata, mama, vejiga, pulmón y/o melanoma.
CO2019005165A2 (es) Compuesto de piridona como inhibidor de c-met
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
UA113643C2 (xx) N-цикліламіди як нематоциди
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
AR091857A1 (es) INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
ECSP14013222A (es) Indazoles
MX373196B (es) Inhibidores de histona desacetilasa novedosos.
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
CO2019011604A2 (es) Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos
AR094959A1 (es) Compuestos de imidazo piridina
ES2657549T3 (es) Piridopirazinas sustituidas como nuevos inhibidores de SYK
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
NI201400134A (es) Novedosas n - piridinil amidas cíclicas sustituidas como inhibidores de quinasa.
CU24330B1 (es) Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
CR20160202A (es) Procedimiento de preparación de una sal de tipo camsilato
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
AR101359A1 (es) Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo
AR104331A1 (es) Derivados de tetrazol
AR097739A1 (es) Imidazo[1,2-a]piridina-7-aminas
CO2020005944A2 (es) Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y métodos de síntesis de los mismos
AR101528A1 (es) Inhibidores de cdk9 quinasa de pirrolo[2,3-b]piridina

Legal Events

Date Code Title Description
FB Suspension of granting procedure